CN1617755A - 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用 - Google Patents

法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用 Download PDF

Info

Publication number
CN1617755A
CN1617755A CNA028239202A CN02823920A CN1617755A CN 1617755 A CN1617755 A CN 1617755A CN A028239202 A CNA028239202 A CN A028239202A CN 02823920 A CN02823920 A CN 02823920A CN 1617755 A CN1617755 A CN 1617755A
Authority
CN
China
Prior art keywords
amount
day
administered
fpt inhibitor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028239202A
Other languages
English (en)
Chinese (zh)
Inventor
D·L·库特勒尔
M·L·迈尔斯
C·鲍姆
S·L·扎克诺恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1617755A publication Critical patent/CN1617755A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA028239202A 2001-11-30 2002-11-25 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用 Pending CN1617755A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33441101P 2001-11-30 2001-11-30
US60/334,411 2001-11-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2007101860344A Division CN101181269A (zh) 2001-11-30 2002-11-25 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用

Publications (1)

Publication Number Publication Date
CN1617755A true CN1617755A (zh) 2005-05-18

Family

ID=23307076

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA028239202A Pending CN1617755A (zh) 2001-11-30 2002-11-25 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用
CNA2007101860344A Pending CN101181269A (zh) 2001-11-30 2002-11-25 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2007101860344A Pending CN101181269A (zh) 2001-11-30 2002-11-25 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用

Country Status (13)

Country Link
US (2) US20030185831A1 (https=)
EP (1) EP1448268A2 (https=)
JP (1) JP2005511663A (https=)
CN (2) CN1617755A (https=)
AU (1) AU2002352941A1 (https=)
BR (1) BR0214564A (https=)
CA (1) CA2468839A1 (https=)
HU (1) HUP0402401A2 (https=)
MX (1) MXPA04005207A (https=)
NO (1) NO20042730L (https=)
NZ (1) NZ532562A (https=)
WO (1) WO2003047697A2 (https=)
ZA (1) ZA200403737B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533838A (ja) * 2002-07-24 2005-11-10 ノバルティス　アクチエンゲゼルシャフト 未分化甲状腺癌を処置するための４−（４−メチルピペラジン−１−イルメチル）−ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イルアミノ］フェニル］−ベンズアミド
CA2439440A1 (en) * 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
CA2544421A1 (en) * 2003-11-06 2005-05-26 Schering Corporation Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer
JP2007525507A (ja) * 2004-02-26 2007-09-06 ザ ペン ステイト リサーチ ファンデーション オピオイド増殖因子レセプターを用いる、新生物の処置のための組み合わせ療法
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20080255171A1 (en) * 2005-10-07 2008-10-16 Manley Paul W Combination of Nilotinib with Farnesyl Transferase Inhibitors
WO2008051531A2 (en) * 2006-10-25 2008-05-02 Schering Corporation Discontinuous methods of treating cancer
WO2008067144A2 (en) * 2006-11-28 2008-06-05 Smithkline Beecham (Cork) Limited Cancer treatment method
US20230390197A1 (en) * 2020-10-27 2023-12-07 Wisconsin Alumni Research Foundation Modular dendron micelles for combination immunotherapy
AU2023376684A1 (en) 2022-11-09 2025-06-19 Merck Patent Gmbh Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
DK1041985T3 (da) * 1997-12-22 2006-06-19 Schering Corp Kombination af benzocycloheptapyridinforbindelser og antineoplastiske lægemidler til behandling af profilerative sygdomme
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
JP5491681B2 (ja) * 2000-02-04 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
US6838467B2 (en) * 2000-02-24 2005-01-04 Janssen Pharmaceutica N. V. Dosing regimen
CA2397448A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
JP2003525239A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
EP1322334A2 (en) * 2000-10-05 2003-07-02 George Q. Daley Methods of inducing cancer cell death and tumor regression

Also Published As

Publication number Publication date
NO20042730L (no) 2004-06-29
WO2003047697A2 (en) 2003-06-12
AU2002352941A1 (en) 2003-06-17
ZA200403737B (en) 2005-05-23
WO2003047697A3 (en) 2003-10-30
MXPA04005207A (es) 2004-08-19
US20060183765A1 (en) 2006-08-17
CA2468839A1 (en) 2003-06-12
JP2005511663A (ja) 2005-04-28
HUP0402401A2 (hu) 2005-03-29
EP1448268A2 (en) 2004-08-25
CN101181269A (zh) 2008-05-21
NZ532562A (en) 2007-02-23
US20030185831A1 (en) 2003-10-02
BR0214564A (pt) 2004-11-09

Similar Documents

Publication Publication Date Title
CN1419452A (zh) 协同治疗癌症的方法和组合物
CN1496256A (zh) 用于治疗增生性疾病的埃博霉素(epo thilone)类似物和化疗剂的组合
CN1735415A (zh) 使用免疫调节化合物治疗和控制癌症和其他疾病的方法和组合物
CN1711094A (zh) Src家族非受体酪氨酸激酶抑制剂和吉西他滨的组合产品
CN1774265A (zh) 神经再生药
CN101039673A (zh) 用于治疗涉及细胞增殖的疾病的组合
CN1366881A (zh) 用雌激素激动剂/拮抗剂治疗某些癌症的方法
CN1155572C (zh) 吲哚类衍生物及其抗肿瘤用途
CN1668296A (zh) 使用选择性细胞因子抑制性药物用于治疗和控制癌症和其它疾病的方法及组合物
CN1655784A (zh) 有效的选择性阿片受体调制剂化合物的用途
CN1835948A (zh) 2－酰基氨基噻唑衍生物或其盐
CN1617755A (zh) 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用
CN101080227A (zh) 用于治疗癌症的治疗剂的组合
CN1610549A (zh) 用于治疗难治肿瘤的埃坡霉素衍生物
CN1735412A (zh) 利用选择性细胞因子抑制药物治疗和控制癌症和其它疾病的方法和组合物
CN1129431C (zh) 苯并芳庚并吡啶类化合物与抗肿瘤药联合用于治疗增生性疾病
CN1668299A (zh) 使用jnk抑制剂治疗或预防与疾病－相关的消瘦的方法
CN1117092C (zh) 氮杂双环化合物,其药物组合物及医药用途
CN1784232A (zh) 包含抗血管生成剂和Src抑制剂的联合的治疗药物及其治疗用途
CN1849119A (zh) 用于增生性疾病的治疗的src激酶抑制剂和化学治疗剂的组合
CN1139383C (zh) 用于借助细胞毒试剂治疗肿瘤过程的含异黄酮类的治疗组合物
CN1805749A (zh) 星孢素衍生物的新药物用途
CN1832747A (zh) 包含星孢素的组合
CN1139384C (zh) 用于与细胞毒性剂治疗肿瘤的基于类黄酮的治疗组合物
CN1509763A (zh) 人肿瘤坏死因子-α突变体的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication